创生控股Trauson Holdings

　 创生控股有限公司（「创生控股」或「本公司」）及其附属公司（统称「本集团」或「集团」）是中国领先的骨科产品生产商，主要从事设计、制造及销售多种创伤及脊柱骨科植入物，以及相关手术工具。集团正式始建于二零零二年十二月，由现任董事会主席兼首席执行官钱福卿先生创办，是中国骨科市场的首批进入者之一。根据权威机构统计，创生控股以市场份额计算是中国骨科产品生产商中最大的创伤产品生产商及三大脊柱产品生产商之一。

　　截至二零一零年十二月三十一日，集团共有一百余种产品，并透过旗下品牌－「创生」及「奥斯迈」销售。集团庞大的分销网络覆盖全国三十个省市及自治区，有超过三千家医院认可创生控股为骨科产品供货商。

　　集团秉承「专业、专注、专心」的理念，自创建以来取得了迅速的增长。创生控股于二零一零年六月二十九日在其发展过程中取得了一个重要的里程碑，成功于香港联合交易所有限公司（「香港联交所」）主板上市（股份代号 325.HK ），成为为数不多的进入国际资本市场的中国骨科器械企业之一。
 

　　 创生控股旗下拥有两家主要的全资控股企业：创生医疗器械（江苏）有限公司（「创生江苏」已于二零一一年三月二十三日更名为创生医疗器械（中国）有限公司）和常州奥斯迈医疗器械有限公司（「常州奥斯迈」）。于二零一零年十二月三十一日，本集团分别有三个厂区，总楼面面积达107,100平方米，集团的总资产达人民币10.23亿元。

　　集团拥有精良的制造加工设备及测量仪器，通过了中国医疗器械质量认证中心的ISO13485-2003质量体系认证，截止2010年底，公司获得产品注册证书100份，主要产品于2007年获CE认证证书、2008年获美国药监局510（K）许可。「创生」商标被认定为中国驰名商标，是中国骨科领域唯一获此殊荣的公司。

Trauson Holdings Company Limited (Trauson Holdings or the Company) and its subsidiaries (together as the Group) is a leading manufacturer of orthopaedic products in China. The Group was founded in December 2002 by the chairman and chief executive officer,Mr.Qian Fuqing,who is one of the forerunners in Chian''''''''''''''''s orthopaedic industry. According to an authoritative statistics, Trauson Holdings was the largest domestic producer of trauma products and one of the top three domestic producers of spine products in China by market share.
 

As at 31 December 2010, the Group had over 100 products marketed under its own brands, Trauson and Orthmed. The Groups extensive distribution network covered over 30 provinces and autonomous regions across China, with over 3,000 hospitals recognizing Trauson Holdings as their supplier of orthopaedic products.

Embracing the philosophy of professionalism, focus and concentration, the Group has experienced rapid growth since its inception. On 29 June 2010, Trauson Holdings reached an important milestone in its development when it was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (the HKSE) (stock code: 325.HK), becoming one of the first China orthopaedic device companies to access the international capital market.

The Group has two principal and wholly-owned operating subsidiaries, Trauson (Jiangsu) Medical Instrument Company Limited (Trauson Jiangsu, which has been renamed as Trauson Medical Instrument (China) Company Limited with effect from 23 March 2011) and Changzhou Orthmed Medical Instrument Company Limited (Changzhou Orthmed). As at 31 December 2010, the Group had three production facilities with an aggregate floor area of 107,100 square metres, and total assets of approximately RMB1,023 million.

With the introduction of sophisticated manufacturing and processing equipments and measuring instruments, Trauson Holdings has also obtained the ISO13485-2003 certification of the China Quality Certification Center for Medical Devices. By the end of 2010, Trauson Holdings had received 100 registration certificates for its products. In addition, Trauson Holdings main product had attained CE marks and US FDA 510(K), in 2007 and 2008 respectively. TRAUSON is the only trademark that has been awarded the Well-known Chinese Brand in Chinas orthopaedic industry.